-
Dobbs Revisited — Addressing Effects on Resident Training in Obstetrics and Gynecology N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-21 Abigail S. Cutler, and Ellen Hartenbach From the Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison.
After the Dobbs decision, an Ob/Gyn residency program in Wisconsin had to send its residents out of state to obtain abortion training. The process was complicated and costly.
-
Button-Battery Ingestion N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-21 Miriam R. Smetak Washington University in St. Louis School of Medicine, St. Louis, MO, Lyndy J. Wilcox Vanderbilt University Medical Center, Nashville, TN
An 11-month-old girl presented with a 2-week history of progressive dysphagia and cough. A chest radiograph showed a foreign body with a “double-ring” sign. Torrential hematemesis subsequently deve...
-
How DNA Sensing Drives Inflammation N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Elizabeth G. Phimister, Russell E. Vance From the Howard Hughes Medical Institute and the Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley.
The 2024 Albert Lasker Award for Basic Medical Research recognizes Dr. Zhijian (James) Chen for his elucidation of how DNA stimulates immune responses.
-
Discovery of GLP-1–Based Drugs for the Treatment of Obesity N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Elizabeth G. Phimister, Daniel J. Drucker From the Department of Medicine, Lunenfeld–Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto.
The 2024 Lasker–DeBakey Clinical Medical Research Award recognizes Drs. Habener, Mojsov, and Knudsen, who developed GLP-1 medicines that have revolutionized the treatment of obesity.
-
Newborn Screening and Presymptomatic Treatment of Metachromatic Leukodystrophy N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-18 Lucia Laugwitz University Hospital Tübingen, Tübingen, Germany, Thomas P. Mechtler ARCHIMEDlife Medical Laboratories, Vienna, Austria, Nils Janzen Screening Laboratory Hannover, Hannover, Germany, Petra Oliva ARCHIMEDlife Medical Laboratories, Vienna, Austria, Andrea-Romana Kasper Medical University of Vienna, Vienna, Austria, Charlotte E. Teunissen Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
In a pilot program in which 109,259 newborns were screened for metachromatic leukodystrophy, blood-spot samples were obtained for analysis and three newborns with MLD were identified, which made pr...
-
Fabry’s Disease N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Stephen Soloway, and Denise Lister Arthritis and Rheumatology Associates of South Jersey, Vineland, NJ
A 44-year-old man presented with a 5-year history of heat intolerance and burning pain in his hands and feet. He had periumbilical angiokeratomas and nonnephrotic proteinuria. A kidney biopsy was p...
-
House Staff Unionization — A Historical Tool Revisited N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Debra Malina, Ahmed Ahmed, and Scott H. Podolsky From the Department of Internal Medicine, Brigham and Women’s Hospital (A.A.), and the Department of Global Health and Social Medicine, Harvard Medical School (S.H.P.) — both in Boston.
As more and more U.S. residents unionize, examination of the history of house staff organizing highlights the enduring rationales for unionization, as well as the precipitating and resulting tensions.
-
Targeting CSF1R in Chronic GVHD — Lessons in Translation N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Stefanie Sarantopoulos From the Division of Hematological Malignancies and Cellular Therapy, Duke University Department of Medicine, Department of Integrative Immunology, Duke Cancer Institute, Durham, NC.
Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise cured by means ...
-
Bending the Overdose Curve — Still Not Enough N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Daniel Ciccarone From Family and Community Medicine, University of California San Francisco, San Francisco.
The multiple waves of overdose deaths in the United States continue to morph in new and unexpected directions, now driven by fentanyl used in combination with other substances.1 Despite our public ...
-
Two Clinical Trials Assessing Treatments for Eosinophilic Esophagitis N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19
To the Editor: Chehade et al. (June 27 issue)1 explored the therapeutic effect of dupilumab in children with eosinophilic esophagitis. We have several concerns regarding the conclusions and methods...
-
Noninvasive Ventilation for Preoxygenation during Emergency Intubation N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19
To the Editor: In their article regarding the Pragmatic Trial Examining Oxygenation Prior to Intubation (PREOXI), Gibbs et al. (June 20 issue)1 compared preoxygenation by means of either positive-p...
-
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Hanny Al-Samkari, Raj S. Kasthuri, Vivek N. Iyer, Allyson M. Pishko, Jake E. Decker, Clifford R. Weiss, Kevin J. Whitehead, Miles B. Conrad, Marc S. Zumberg, Jenny Y. Zhou, Joseph Parambil, Derek Marsh, Marianne Clancy, Lauren Bradley, Lisa Wisniewski, Benjamin A. Carper, Sonia M. Thomas, and Keith R. McCrae From Massachusetts General Hospital, Boston (H.A.-S.), University of North Carolina, Chapel
Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in iron-defic...
-
CSF1R Blockade for Refractory Chronic Graft-versus-Host Disease. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Mohamad Mohty
-
Case 29-2024: A 47-Year-Old Man with Confusion and Kidney Failure. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Sachin J Shah,Melissa C Price,Sanjat Kanjilal
-
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-19 Daniel Wolff,Corey Cutler,Stephanie J Lee,Iskra Pusic,Henrique Bittencourt,Jennifer White,Mehdi Hamadani,Sally Arai,Amandeep Salhotra,Jose A Perez-Simon,Amin Alousi,Hannah Choe,Mi Kwon,Arancha Bermúdez,Inho Kim,Gerard Socié,Saurabh Chhabra,Vedran Radojcic,Timothy O'Toole,Chuan Tian,Peter Ordentlich,Zachariah DeFilipp,Carrie L Kitko,
BACKGROUND Colony-stimulating factor 1 receptor (CSF1R)-dependent monocytes and macrophages are key mediators of chronic graft-versus-host disease (GVHD), a major long-term complication of allogeneic hematopoietic stem-cell transplantation. The CSF1R-blocking antibody axatilimab has shown promising clinical activity in chronic GVHD. METHODS In this phase 2, multinational, pivotal, randomized study
-
No One in Charge N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-14 Janet R. Gilsdorf From the University of Michigan Medical School, Ann Arbor.
A chance encounter with a retired military officer who recently lost his wife to cancer raises questions for a retired pediatrician about medical hierarchy, team leadership, and appropriate care.
-
The Sense and Sensibility of Sensitivity Analyses N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-14 Debbie M. Cheng, and Joseph W. Hogan From the Department of Biostatistics, Boston University School of Public Health, Boston (D.M.C.), and the Department of Biostatistics, Brown University School of Public Health, Providence, RI (J.W.H.).
Sensitivity analyses are instrumental in assessing the robustness of trial findings. Thoughtful planning is needed to ensure they are conducted and reported properly.
-
Flail Chest N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-14 Zhi Hu, and Biao Wang Affiliated Hospital of Southwest Medical University, Luzhou, China
A 59-year-old man was brought to the emergency department after a motor vehicle collision. Paradoxical movement of a segment of his chest wall during respiration was noted on examination (shown in ...
-
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-15 Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Parikh, Min Yuen Teo, Randy F. Sweis, Daniel M. Geynisman, Petros Grivas, Gurkamal Chatta, Zachery Roger Reichert, Joseph W. Kim, Mehmet Asim Bilen, Bradley McGregor, Parminder Singh, Abhishek Tripathi, Suzanne Cole, Nicholas Simon, Scot Niglio, Lisa Ley, Lisa Cordes, Sandy Srinivas, Jiaoti Huang, Meagan Odegaard
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive uro...
-
Ponsegromab for the Treatment of Cancer Cachexia N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-14 John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon Lubaczewski, Eric J. Roeland, Tateaki Naito, Andrew E. Hendifar, Marie Fallon, Koichi Takayama, Timothy Asmis, Richard F. Dunne, Isik Karahanoglu, Carrie A. Northcott, Magdalena A. Harrington, Michelle Rossulek, Ruolun Qiu, and Aditi R. Saxena From the Internal Medicine Research Unit (J.D.G., I.K., M.A.H., A.R.S.) and Clinical Pharmacology
Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...
-
Preoperative Chemoradiotherapy for Resectable Gastric Cancer N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-14 Trevor Leong, B. Mark Smithers, Michael Michael, Karin Haustermans, Rebecca Wong, Val Gebski, Rachel L. O’Connell, John Zalcberg, Alex Boussioutas, Michael Findlay, David Willis, Alisha Moore, William K. Murray, Florian Lordick, Chris O’Callaghan, Carol Swallow, Gail Darling, Danielle Miller, Andrew Strickland, Moishe Liberman, Laurent Mineur, and John Simes the Australasian Gastro-Intestinal Trials
In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding th...
-
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-13 Ying Cheng, David R. Spigel, Byoung Chul Cho, Konstantin K. Laktionov, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Ki Hyeong Lee, Qiming Wang, Alejandro Navarro, Reyes Bernabe, Eva Lotte Buchmeier, John Wen-Cheng Chang, Yoshimasa Shiraishi, Sema Sezgin Goksu, Andrzej Badzio, Anhui Shi, Davey B. Daniel, Nguyen Thi Thai Hoa, Milada Zemanova, Helen Mann, Hema Gowda, Haiyi Jiang, and Suresh Senan the ADRIATIC
Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent...
-
Ethical Challenges Associated with Pragmatic and Cluster RCTs. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-14 Charles Weijer,Monica Taljaard
-
Medication for Gastroesophageal Reflux Disease in Infants N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-12 Julie R. Barzilay, Martin T. Stein, and Paula Heimberg
This case vignette of a 3-month-old infant with emesis after feeding and poor growth is accompanied by two essays, one recommending medication and the other supporting nonpharmacologic interventions.
-
Early Diagnosis and Treatment of COPD and Asthma. Reply. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-12 Shawn D Aaron
-
Self-Expanding or Balloon-Expandable TAVR with a Small Aortic Annulus. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-12 Amr E Abbas,Philippe Pibarot,Rebecca T Hahn
-
CML 25 Years Later - Poised for Another Breakthrough? N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-12 Elisabetta Abruzzese
-
Case 28-2024: A 75-Year-Old Woman with Edema, Arthritis, and Proteinuria. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-12 Beth L Jonas,Rene Balza Romero,Lisa G Criscione-Schreiber,Pui W Cheung,Claire Trivin-Avillach
-
Clinical Approaches to the Prevention of Firearm-Related Injury. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-12 Patrick M Carter,Rebecca M Cunningham
-
-
Childhood Obesity and GLP-1 Receptor Agonists — A Coming of Age? N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-10 Timothy Barrett, and Julian Hamilton-Shield From the College of Medicine and Health, University of Birmingham, Birmingham (T.B.), and Bristol Medical School, University of Bristol, Bristol (J.H.S.) — both in the United Kingdom.
Childhood obesity, defined as an age-adjusted and sex-adjusted body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) in the 95th percentile or higher, accordi...
-
Sequencing-Based Detection of Avian Influenza A(H5N1) Virus in Wastewater in Ten Cities. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-11 Michael J Tisza,Blake M Hanson,Justin R Clark,Li Wang,Katelyn Payne,Matthew C Ross,Kristina D Mena,Anna Gitter,Sara J Javornik Cregeen,Juwan Cormier,Vasanthi Avadhanula,Austen Terwilliger,John Balliew,Fuqing Wu,Janelle Rios,Jennifer Deegan,Pedro A Piedra,Joseph F Petrosino,Eric Boerwinkle,Anthony W Maresso
-
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-10 Claudia K Fox,Margarita Barrientos-Pérez,Eric M Bomberg,John Dcruz,Inge Gies,Nina M Harder-Lauridsen,Muhammad Yazid Jalaludin,Kushal Sahu,Petra Weimers,Thomas Zueger,Silva Arslanian,
BACKGROUND No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide has been shown to induce weight loss in adults and adolescents with obesity, its safety and efficacy have not been established in children. METHODS In this phase 3a trial, which consisted of a 56-week treatment period and
-
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-10 Carol Wysham,Harpreet S Bajaj,Stefano Del Prato,Denise Reis Franco,Arihiro Kiyosue,Dominik Dahl,Chunmei Zhou,Molly C Carr,Michael Case,Livia Firmino Gonçalves,
BACKGROUND Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials. METHODS We conducted a 52-week, phase 3, parallel-design, open-label, treat-to-target trial involving adults with type 2 diabetes who had not previously received insulin. Participants were randomly assigned in
-
A New Once-Weekly Insulin - Its Effectiveness and Safety. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-10 Irwin Brodsky
-
Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-10 Magnus Ekström,Anders Andersson,Savvas Papadopoulos,Taivo Kipper,Bo Pedersen,Ozren Kricka,Pierre Sobrino,Michael Runold,Andreas Palm,Anders Blomberg,Ranjh Hamed,Eva Lindberg,Björn Sundberg,Nermin Hadziosmanovic,Filip Björklund,Christer Janson,Christine F McDonald,David C Currow,Josefin Sundh,
BACKGROUND Long-term oxygen supplementation for at least 15 hours per day prolongs survival among patients with severe hypoxemia. On the basis of a nonrandomized comparison, long-term oxygen therapy has been recommended to be used for 24 hours per day, a more burdensome regimen. METHODS To test the hypothesis that long-term oxygen therapy used for 24 hours per day does not result in a lower risk of
-
Making Long-Term Oxygen Therapy Less Burdensome. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-10 Darren B Taichman,Jeffrey M Drazen
-
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-09 David J Jackson,Michael E Wechsler,Daniel J Jackson,David Bernstein,Stephanie Korn,Paul E Pfeffer,Ruchong Chen,Junpei Saito,Gustavo de Luíz Martinez,Lucyna Dymek,Loretta Jacques,Nicholas Bird,Stein Schalkwijk,Douglas Smith,Peter Howarth,Ian D Pavord,
BACKGROUND Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. METHODS In these phase 3A, randomized, placebo-controlled replicate trials, we evaluated the efficacy and safety of depemokimab in patients with severe asthma and an eosinophilic phenotype characterized by a high eosinophil count (≥300
-
Ingesting Risk — The FDA and New Food Ingredients N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-07 Pieter A. Cohen, and Emily M. Broad Leib From Cambridge Health Alliance, Somerville (P.A.C.), Harvard Medical School, Boston (P.A.C.), and the Food Law and Policy Clinic, Harvard Law School, Cambridge (E.M.B.L.) — all in Massachusetts.
Food additives that are “generally recognized as safe” — a determination that can be made by manufacturers — aren’t required to be approved by the FDA. This system could pose a threat to public health.
-
Keeping SNAP in Line with Global Evidence on Food Security. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-07 Benjamin W Chrisinger
-
How Does Health Care Burden Patients? Let Me Count the Days. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-07 Ishani Ganguli
-
Centering the Peripheral Brain - The History of Reference Tools in Medicine. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-07 Andrew S Lea,Scott H Podolsky
-
The Supreme Court’s Shadowy Treatment of Public Health N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-04 Sommer H. Engels, Andrew C. Mergen, Nicholas Nassikas, and Jared Radbel From the Emmett Environmental Law and Policy Clinic, Harvard Law School, Cambridge (S.H.E., A.C.M.), and the Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston (N.N.) — both in Massachusetts, and the Division of Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson
In June 2024, the Supreme Court issued an order halting implementation of a regulation intended to limit the interstate spread of ozone-forming emissions. The decision could endanger human health.
-
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, Nelly Firmin, Pascaline Boudou-Rouquette, François Bertucci, Valérie Lebrun-Ly, Isabelle Ray-Coquard, Elsa Kalbacher, Emmanuelle Bompas, Olivier Collard, Nicolas Isambert, Cécile Guillemet, Maria Rios, Axel Le Cesne, Corinne Balleyguier, Baptiste Archambaud, and Florence Duffaud the French Sarcoma Group*
The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma.We ...
-
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Opeolu Adeoye, Joseph Broderick, Colin P. Derdeyn, James C. Grotta, William Barsan, Oladi Bentho, Scott Berry, Mauricio Concha, Iris Davis, Stacie Demel, Jordan Elm, Nina Gentile, Todd Graves, Melissa Hoffman, Josephine Huang, James Ingles, Scott Janis, Adam S. Jasne, Pooja Khatri, Steven R. Levine, Aniel Majjhoo, Peter Panagos, Arthur Pancioli, Stephanie Pizzella, Tamra Ranasinghe, Noor Sabagha, Sanjeev
Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an...
-
Congenital and Acquired Chiari Syndrome. Reply. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Robert M Friedlander
-
A New Antibody Treatment for Migraine. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Elizabeth Loder
-
BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Melanie Hagen,Laura Bucci,Sebastian Böltz,Danae-Mona Nöthling,Tobias Rothe,Kirill Anoshkin,Maria G Raimondo,Carlo Tur,Andreas Wirsching,Jochen Wacker,Christina Düsing,Jörg H W Distler,Torsten Kuwert,Aline Bozec,Andreas Ramming,Georg Schett,Ricardo Grieshaber-Bouyer
-
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Tobias Alexander,Jan Krönke,Qingyu Cheng,Ulrich Keller,Gerhard Krönke
-
Building a Community of Medical Learning - A Century of Case Records of the Massachusetts General Hospital in the Journal. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Rory Brinkmann,Eric Rosenberg,David N Louis,Scott H Podolsky
-
Case 27-2024: A 24-Year-Old Man with Pain and Dyspnea. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Rochelle P Walensky,Meridale V Baggett,Kathy M Tran,Jo-Anne O Shepard,David M Dudzinski,Dennis C Sgroi
-
A Late-Arriving but Welcome Advance in Sarcoma Therapy. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Robert S Benjamin
-
Primary Cutaneous Herpes Simplex Virus Infection of the Cheek. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Alejandro Claudio-Oliva,Antonio Jose Duran-Romero
-
A New Orthonairovirus Associated with Human Febrile Illness. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Xiao-Ai Zhang,Yi-Dan Ma,Yun-Fa Zhang,Zhen-Yu Hu,Jing-Tao Zhang,Shuo Han,Gang Wang,Shuang Li,Xi Wang,Fang Tang,Wen-Jun Liang,Hong-Xia Yuan,Jia-Qi Zhao,Lan-Fen Jiang,Lei Zhang,Guang-Qian Si,Cong Peng,Rui Wang,Hong-Han Ge,Nan Li,Bao-Gui Jiang,Chang Li,Hao Li,Wei Liu
BACKGROUND In June 2019, a patient presented with persistent fever and multiple organ dysfunction after a tick bite at a wetland park in Inner Mongolia. Next-generation sequencing in this patient revealed an infection with a previously unknown orthonairovirus, which we designated Wetland virus (WELV). METHODS We conducted active hospital-based surveillance to determine the prevalence of WELV infection
-
Electrocardiographic Findings in Diffuse Subendocardial Ischemia. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Manhal Habib,Doron Aronson
-
A Monoclonal Antibody to PACAP for Migraine Prevention. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Messoud Ashina,Ravinder Phul,Melanie Khodaie,Elin Löf,Ioana Florea
BACKGROUND Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) is a new avenue for treating migraine. The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody directed against the PACAP ligand, for migraine prevention are unclear. METHODS In a phase 2, double-blind, randomized, placebo-controlled trial, we enrolled adult participants (18 to 65 years of age)
-
Healing within Kinship - Community and Care on Navajo Nation. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-05 Heather Kovich,Marcus Couldridge,Lance Whitehair,Kevin Begay,Bernadette Bernally,Debra Malina
-
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-01 Min Soo Cho, Do-Yoon Kang, Jung-Min Ahn, Sung-Cheol Yun, Yong-Seog Oh, Chang Hoon Lee, Eue-Keun Choi, Ji Hyun Lee, Chang Hee Kwon, Gyung-Min Park, Hyung Oh Choi, Kyoung-Ha Park, Kyoung-Min Park, Jongmin Hwang, Ki-Dong Yoo, Young-Rak Cho, Ji Hyun Kim, Ki Won Hwang, Eun-Sun Jin, Osung Kwon, Ki-Hun Kim, Seung-Jung Park, Duk-Woo Park, and Gi-Byoung Nam the EPIC-CAD Investigators* From the Department of
Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary a...
-
NEJM at ESC - Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-02 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-09-02 Gerald F Watts,Robert S Rosenson,Robert A Hegele,Ira J Goldberg,Antonio Gallo,Ann Mertens,Alexis Baass,Rong Zhou,Ma'an Muhsin,Jennifer Hellawell,Nicholas J Leeper,Daniel Gaudet,
BACKGROUND Persistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of recurrent acute pancreatitis. Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides. METHODS In a phase 3 trial